University of Pennsylvania-Abramson Cancer Center
University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Residual Cancer, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-05-04 | NCT04434040 | |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-04-29 | NCT04468061 | |
| Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-01-15 | NCT04448886 |